Intuitive Surgical Receives FDA Clearance for da Vinci 5 Robot in Cardiac Procedures
Key Insights
The FDA has cleared Intuitive Surgical's da Vinci 5 (search) robot for nine cardiac procedures including mitral valve repair (search), cardiac revascularization (search), and septal defect repairs.
The clearance covers non-force feedback instruments such as forceps, dissectors, and scissors for minimally invasive cardiac surgery applications.
Surgeons worldwide performed approximately 17,000 cardiac procedures using da Vinci systems in 2025, demonstrating growing adoption of robotic cardiac surgery.
The US Food and Drug Administration has granted clearance for Intuitive Surgical's da Vinci 5 (search) surgical robot to perform cardiac procedures, marking a significant expansion of the platform's capabilities into minimally invasive heart surgery. The clearance encompasses nine specific cardiac procedures and represents a major milestone for robotic surgery in cardiovascular medicine.
Comprehensive Cardiac Procedure Coverage
The FDA clearance covers an extensive range of cardiac interventions including mitral valve repair (search), internal mammary artery mobilization for cardiac revascularization (search), patent foramen ovale (search) closure, atrial septal defect (search) repair, left atrial appendage closure/occlusion, atrial myxoma (search) excision, mitral valve replacement, tricuspid valve repair (search), and epicardial pacing lead placement.
The approval specifically applies to non-force feedback instruments used with the da Vinci 5 (search) system, including key surgical tools such as forceps, dissectors, and scissors. These instruments enable surgeons to perform complex cardiac procedures through minimally invasive approaches.
Strategic Implementation and Training Focus
CEO Dave Rosa emphasized the company's commitment to careful implementation, stating, "Given the complexity of minimally invasive cardiac surgery, we are planning a measured rollout to support training, education, and adoption." The company recognizes the technical demands of cardiac surgery and plans to provide comprehensive support to ensure successful adoption.
"We believe deeply that patients requiring cardiac surgery can benefit from a minimally invasive approach with da Vinci and look forward to actively supporting our customers through these procedures," Rosa added during the company's Q4 2025 earnings call.
Global Adoption and Market Performance
The clearance comes as robotic cardiac surgery gains momentum globally. According to Intuitive Surgical CFO Jamie Samath, surgeons performed approximately 17,000 cardiac procedures worldwide using da Vinci systems in 2025, demonstrating significant adoption of the technology.
The company reported strong financial performance in Q4 2025, with revenues reaching $2.87 billion, representing a 19% increase from $2.41 billion in Q4 2024. William Blair analyst Brandon Vasquez noted that earnings per share exceeded Wall Street expectations by 12%, driven by general growth and increasing da Vinci 5 (search) placements.
Force Feedback Technology Development
While the current clearance covers non-force feedback instruments, Intuitive continues developing force feedback capabilities for cardiac applications. The da Vinci 5 (search), which received FDA clearance in March 2024, was the first Intuitive robot to introduce force technology, enabling surgeons to feel subtle forces exerted on tissue during surgery.
"Since cardiac surgery is a wide variety of procedures with a wide variety of tasks, we think that force feedback can have some benefit in certain parts of certain procedures," Rosa explained. The company is working on foundational aspects for force feedback instruments in cardiac indications and pursuing approvals in Europe and other international markets.
Market Impact and Future Outlook
Following the earnings announcement, Intuitive's shares rose approximately 0.8% to $530 per share at market open, reflecting investor confidence in the company's expansion into cardiac surgery. With a market capitalization of $189.08 billion, Intuitive continues to lead the robotic surgery market.
The cardiac clearance represents a strategic expansion for Intuitive, potentially opening new revenue streams in a specialized surgical field where minimally invasive approaches can significantly benefit patient outcomes. The company's measured approach to rollout, emphasizing training and education, positions it to capture market share while maintaining safety standards in this complex surgical domain.